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Original article
Current estimates are that 4% of US children overall, and up 
to 10% of underrepresented minority children, have hyper-
tension (HTN).1 Furthermore, 10% of obese children are 
hypertensive, a remarkably high number given that nearly 
20% of US adolescents are obese.2 This striking prevalence 
of primary pediatric HTN has important public health 
implications for the long-term development of HTN-related 
morbidity in such children, including stroke, myocardial 
infarction, and kidney failure. It is clear that the origins 
of HTN-associated morbidity begin during childhood, 
as manifested by the common presence of left ventricular 
hypertrophy and increased carotid intima–media thick-
ness in children with primary HTN.3,4 There is emerging 
evidence that target organ damage to the brain may begin 
during childhood as well. Young adults with primary HTN 
demonstrate decreased performance on neurocognitive 
testing, a finding which has been proposed to represent an 
early manifestation of hypertensive target organ damage to 
the brain.5–7 Similar to the adult findings, preliminary stud-
ies suggest that children with primary HTN score lower on 
measures of neurocognition compared with normotensive 
controls.8–10
With funding from the National Institutes of Health, we 
have established an ongoing prospective, multicenter study 
of neurocognition in children with primary HTN in order to 
more definitively evaluate the relation between cognition and 
HTN in children.11 A potential confounding variable in the 
investigation of cognition and HTN is the presence of sleep 
disordered breathing (SDB). Children with primary HTN 
are often obese, and obesity, in turn, is often associated with 
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Background
Cognitive test performance is decreased in hypertensive adults and 
children, a finding postulated to represent early target-organ dam-
age to the brain. Hypertensive children are often obese, a comorbid-
ity associated with sleep disordered breathing (SDB), itself associated 
with cognitive problems; potentially confounding the relation between 
hypertension (HTN) and neurocognition. Our objective was to deter-
mine the association between SDB as measured by a scale and ques-
tionnaire score and neurocognition among participants enrolled in an 
ongoing multicenter study of cognition in children with HTN.
METHodS
Subjects completed laboratory-based neurocognitive tests. Parents 
and subjects completed rating scales of executive function, mood, and 
behavior problems. Parents completed the Sleep-Related Breathing 
Disorder scale of the Pediatric Sleep Questionnaire (SRBD-PSQ).
rESuLTS
To date, 38 HTN subjects and 34 control subjects have completed 
neurocognitive testing and the SRBD-PSQ. Median SRBD-PSQ scores 
were similar between groups but the HTN group had a higher per-
centage of subjects with SRBD-PSQ scores in the range suggestive 
of obstructive sleep apnea (26% vs. 6%, P  =  0.03). Overall, higher 
SRBD-PSQ scores were not significantly associated with worse per-
formance on laboratory-based measures of executive function and 
other cognitive domains but were significantly associated with 
worse scores on rating scales of executive function as well as mood 
and behavior problems.
concLuSionS
A larger proportion of children with HTN had scores suggestive of 
SDB. The results underscore the importance of using a multi-method 
approach in the assessment of cognition and adjusting for potential 
confounding effects of SDB in studies of cognition in hypertensive 
children.
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SDB,12 an entity itself associated with cognitive and behav-
ioral problems.13 Therefore, SDB potentially confounds the 
relation between HTN and cognition. While children with 
known obstructive sleep apnea (OSA) are excluded from 
the current study, the diagnosis of OSA is often unrecog-
nized.14 Thus, the extent to which SDB explains the associa-
tion between HTN and cognitive deficits is unknown. The 
objectives of this study are (i) to determine the prevalence 
of SDB in our carefully selected study population and (ii) to 
examine the potential impact of SDB on the neurocognitive 
and behavioral measures being used in the current study of 
cognition in children with HTN.
METHodS
The design of our ongoing study of cognition in HTN 
has been described in detail.11 Briefly, both hypertensive 
and control subjects complete a baseline (pre-intervention) 
assessment consisting of laboratory evaluation, behavioral 
measures, and neurocognitive testing. The hypertensive sub-
jects are then treated according to national consensus guide-
lines and local standards.15 After a 12-month period, the 
same neurocognitive testing is repeated in both the hyper-
tensive and control subjects. The overall goal is to recruit a 
total of 75 newly diagnosed, untreated hypertensive children 
aged 10–18 years old. All hypertensive subjects are required 
to have clinic blood pressure (BP) ≥ 95th percentile and sus-
tained HTN confirmed by 24-hour ambulatory BP monitor-
ing (ABPM).16 For comparison, 75 normotensive, healthy 
10- to 18-year old children are being recruited, and control 
subjects are required to have clinic BP < 95th percentile and 
normotension confirmed by ABPM.16 The control group is 
frequency matched (not individually matched) to the hyper-
tensive group for maternal education, sex, and proportion 
with obesity (body mass index (BMI) ≥ 95th percentile). 
Exclusion criteria include secondary HTN, medication for 
inattention, cognitive impairment, current antihyperten-
sive medication, chronic disease, history of chelation for 
lead, and a previous sleep study diagnosis of OSA. The 
study was approved by each participating sites Institutional 
Review Board.
neurocognitive test battery and behavior measures
Selected measures from baseline neurocognitive assess-
ments were assessed in this analysis and included both 
behavior rating scales and performance-based labora-
tory measures. Laboratory measures of executive function 
included tests of attention regulation, problem solving and 
planning, and set shifting and working memory.17–20 The 
battery also included laboratory measures of fine-motor 
dexterity, intellectual functioning, and verbal learning and 
memory.21
Behavior rating scales included parent and child ratings 
of executive function, mood, and behavior problems.22–25 
Therefore, the cognitive domain of executive function was 
assessed by both laboratory measures and rating scales. 
Laboratory measures of executive function are useful in 
assessing the capacity of the individual subject, whereas 
rating scales (questionnaires completed by the subject or 
parent) evaluate behavioral correlates of executive function 
in the context of real-life distractions and are therefore pro-
posed to be more valid in the assessment of executive func-
tion in daily life.26 Ratings scales and performance-based 
(i.e., laboratory) measures are felt to tap somewhat differ-
ent dimensions of executive function, with both contribut-
ing important information to the clinical understanding of 
the child.27 For these reasons, a multi-method approach that 
included both behavior ratings and laboratory-based meas-
ures was used for the assessment of the cognitive domain of 
executive function.
Table  1 lists all neurocognitive and behavioral rating 
scales by domain.
Measure of disordered sleep
Parents complete the validated 22-item Sleep-Related 
Breathing Disorder scale of the Pediatric Sleep Questionnaire 
(SRBD-PSQ).14,28 The survey queries about snoring, daytime 
sleepiness, and inattention. It is commonly used to assess for 
OSA risk in pediatric research studies but is not meant to 
replace nocturnal polysomnography in the patient care setting 
or to render a clinical diagnosis of OSA. Higher scores repre-
sent worse disordered sleep, and scores > 0.33 are suggestive 
of high risk for a pediatric sleep-related breathing disorder.
Statistical analyses
Demographic data are expressed as mean ± SD or median 
and interquartile range, where appropriate. Two-tailed t 
test or the Wilcoxon rank sum test were used to examine 
demographic differences between the hypertensive and 
control groups for continuous variables and Fisher exact 
test was used for categorical variables. Obesity and morbid 
obesity were defined as BMI ≥ 95th and ≥99th percentile, 
respectively.
For the first study objective, the prevalence of elevated 
SDB in the study population overall was determined by cal-
culating the proportion of subjects with a SRBD-PSQ score 
of ≥0.33. The differences in SDB between the HTN and 
control groups were examined by comparing group median 
SRBD-PSQ scores using the Wilcoxon rank sum test and by 
comparing the proportion of subjects in each group with a 
SRBD-PSQ score ≥ 0.33 using the Fisher exact test.
For the second study objective, the potential impact of 
SDB on the neurocognitive and behavioral measures was 
evaluated for all study subjects combined. Spearman correla-
tion coefficients were used to examine correlations between 
SRBD-PSQ scores and neurocognitive and behavior meas-
ures. In addition, neurocognitive and behavior scores for 
subjects with SRBD-PSQ scores ≥ 0.33 (elevated SDB) were 
compared to those of subjects with SRBD-PSQ scores < 0.33 
using 2-tailed t tests. Cohen’s d effect sizes for this compari-
son were calculated to express the magnitude of the differ-
ence between the elevated SDB and nonelevated SDB groups. 
An effect size of 0.2 is considered small; 0.5, medium; and 
≥0.8, large. We considered an effect size of medium or larger 
as clinically meaningful. P values < 0.05 were considered sig-
nificant for all analyses. Statistical analysis was performed 
using SAS for Windows 9.1 (SAS Institute, Cary, NC).




To date, 38 hypertensive (HTN) subjects and 34 control 
subjects have completed both the SRBD-PSQ and the base-
line neurocognitive assessment, for a total of 72 subjects 
available for analysis. The HTN and control groups are simi-
lar in age, sex, maternal education level, percent obese, and 
significantly different in ambulatory BP, as expected by study 
design. Despite the similar proportion of obese subjects 
(BMI ≥ 95th percentile) between groups, the HTN group 
had a higher median BMI percentile and a higher propor-
tion with morbid obesity (BMI ≥ 99th percentile) (Table 2).
Prevalence of SdB in the study population
Twelve of the 72 subjects (17%) had an elevated SRBD-PSQ 
score of ≥0.33, suggesting high risk for OSA. All 12 subjects 
with an elevated SRBD-PSQ score had a BMI of at least the 
95th percentile, and 9 (75%) had morbid obesity. The HTN 
group had a similar median SRBD-PSQ score compared with 
that of control subjects (0.18, interquartile range: 0.09–0.35 vs. 
0.15; interquartile range: 0.05–0.27, P = 0.27). However, 26% of 
the HTN group had an elevated SRBD-PSQ score ≥ 0.33 com-
pared with only 6% of the control group (P = 0.03, Figure 1).
association between SdB and the neurocognitive and 
behavioral measures
Table 3 shows the correlations between SRBD-PSQ scores 
and scores on the neurocognitive battery and behavioral 
assessments. Overall, higher disordered sleep score was not 
significantly associated with worse performance on the lab-
oratory measures of cognition. By contrast, higher SRBD-
PSQ score was associated with significantly worse ratings 
of executive function, on both the parent and self Behavior 
Rating Inventory of Executive Function (BRIEF). In addi-
tion, higher SRBD-PSQ score was associated with worse 
internalizing and externalizing behavior on the parent-com-
pleted Child Behavior Checklist and worse ratings of depres-
sion on the subject-completed Child Depression Inventory.
Table 1. Neurocognitive and behavior measures
Performance-based measuresa
Domain Test name
Attention/Response Inhibition Conners’ Continuous Performance Test-II (CPT-II)
Problem Solving/Planning CogState Groton Maze Learning Task (GMLT)
Delis-Kaplan Executive Function System (DKEFS), Tower Test
Set Shifting CogState Set Shifting Task
Working Memory Wechsler Intelligence Scale for Children-4th ed (WISC-IV), Spatial Span
WISC-IV Digit Span
Fine Motor Dexterity Grooved Pegboard Test
General Intellectual Ability Wechsler Abbreviated Scales of Intelligence (WASI)
Verbal Learning & Memory Rey Auditory Verbal Learning Test
Behavior rating scalesa,b
Sleep Disordered Breathing Pediatric Sleep Questionnaire: Sleep-Related Breathing Disorder scale (SRBD-PSQ)
Executive Function Behavior Rating Inventory of Executive Function—Parent Formb
BRIEF—Self-Report (Child) Forma
General mood and behavior Achenbach Child Behavior Checklist (CBCL)b
Depression Child Depression Inventorya
Anxiety Multidimensional Anxiety Scale for Childrena
aCompleted by child.
bCompleted by parent.







Age, years 15.0 ± 2.1 15.2 ± 1.9 0.67
Sex, % male 76.3 76.5 0.99
Maternal education ≤ 
high school, %
47.4 44.1 0.82
Minority,a % 47.4 35.3 0.34
BMI percentilea 99 (90 – 99) 97 (92 – 98) 0.05
Obesity, % 71 61.8 0.46
Morbid obesity, % 50 11.8 < 0.01
24-hour SBP load 55.1% 7.2% < 0.01
24-hour DBP load 47.9% 5.3% < 0.01
Abbreviations: BMI, body mass index; DBP, diastolic blood pres-
sure; HTN, hypertension; SBP, systolic blood pressure.
aMinority = AA race or Hispanic ethnicity.
bMedian (interquartile range).
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To further evaluate the impact of SDB on the neurocogni-
tive and behavioral measures being used in the current study 
of cognition in children with HTN, we also compared scores 
of subjects with elevated SDB to those of subjects without 
elevated SDB. Table 4 compares neurocognitive test perfor-
mance and behavior measures for subjects felt to be at high-
est risk for SDB (SRBD-PSQ score ≥ 0.33) to those of subject 
with lower SRBD-PSQ score. Subjects with elevated SRBD-
PSQ performed similar to those subjects without elevated 
SRBD-PSQ on the laboratory performance-based meas-
ures. By contrast, subjects with elevated SRBD-PSQ score 
obtained higher ratings (indicative of greater problems) 
on parent and self-ratings of executive function with large 
effect sizes of clinically meaningful magnitude of 0.94 and 
1.37, respectively. Subjects with elevated SRBD-PSQ score 
also had higher scores (i.e., greater problems) on the Child 
Behavior Checklist and Child Depression Inventory.
diScuSSion
Hypertensive children are often obese, and obese children 
are at increased risk of OSA and upper airway resistance syn-
drome. OSA is characterized by upper airway obstruction 
with the cessation of ventilation despite respiratory effort. 
Upper airway resistance syndrome is characterized by par-
tial obstruction of the upper airway causing arousals and 
sleep fragmentation without gas exchange abnormalities.12 
Children with SDB of either type are at increased risk of exces-
sive daytime sleepiness, behavioral problems, inattention, 
and learning problems.29 In the current ongoing National 
Institutes of Health–funded study of the effect of primary 
HTN on cognition in children, potential subjects with a previ-
ous sleep study diagnosis of OSA are excluded. However, this 
criterion is not expected to be adequate to prevent all subjects 
with SDB from entering the study, and performing noctur-
nal polysomnography on all potential subjects was felt to be 
impractical. Instead, the SRBD-PSQ is included in the battery 
of study assessments to allow for adjustment of results for the 
impact of SDB on cognition. In this analysis, we therefore set 
out to determine the prevalence of SDB in our study cohort to 
date and to determine the potential impact that SDB may have 
as a confounder in the investigation of the effect of primary 
HTN on cognition in this study population.
We found that SDB was common in the primary HTN group, 
with approximately one-quarter of the HTN subjects enrolled 
to date having elevated SRBD-PSQ scores in the range sugges-
tive of OSA compared with less than 10% of the control group. 
There are 2 likely explanations for this difference between the 
HTN and control groups. First, studies in children suggest that 
OSA is associated with elevated BP, independent of obesity.30 
Therefore, subjects selected for elevated BP would be expected 
to have a higher prevalence of SDB compared with subjects 
selected for normotension. Second, studies have shown that 
the degree of SDB in children is proportional to the degree of 
obesity.31,32 While the HTN and control groups were balanced 
in the proportion with obesity overall, the HTN group had a 
higher proportion with morbid obesity. The higher percentage 
of subjects with elevated SDB scores in the HTN group may be 
due, in part, to the higher proportion in that group with severe 
obesity. The lower proportion of subjects with morbid obesity 
Table 3. Neurocognitive test correlation with disordered sleep score





  RAVLT Long Delayed Recall −0.11 0.35
  CogState GMLT Delayed Recall 0.08 0.48
 Attention
  CPT-II Omission errors −0.02 0.88
  Spatial Span Forward −0.05 0.66
  Digit Span Forward −0.05 0.65
 Executive function
  CPT-II Omission errors 0.02 0.84
  Spatial Span Forward −0.08 0.52
  Digit Span Forward −0.13 0.28
  DKEFS Tower total achievement −0.01 0.92
  CogState GMLT Total Error 0.19 0.12
  CogState Set Shifting 0.09 0.47
 Fine motor
  Grooved Pegboard, dominant 0.09 0.43
Questionnaires
 Parent BRIEF GEC 0.49 <0.01
 Self BRIEF GEC 0.45 <0.01
 MASC total 0.12 0.32
 CDI total 0.41 <0.01
 CBCL internalizing 0.45 <0.01
 CBCL externalizing 0.45 <0.01
Abbreviations: BRIEF, Behavior Rating Inventory of Executive 
Function; CBCL, Child Behavior Checklist; CDI, Child Depression 
Inventory; CPT-II, Conners’ Continuous Performance Test-II; DKEFS, 
Delis-Kaplan Executive Function System; GEC, Global Executive 
Composite; GMLT, Groton Maze Learning Test; MASC, Multidimensional 
Anxiety Scale for Children; RAVLT, Rey Auditory Verbal Learning Test.
Figure  1. Proportion of subjects in the control and HTN groups 
with SRBD-PSQ score ≥ 0.33, suggestive of obstructive sleep apnea. 
Abbreviations: HTN, hypertension; SRBD-PSQ, Sleep-Related Breathing 
Disorder scale of the Pediatric Sleep Questionnaire.
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in the control group compared with the HTN group is likely 
a result of the exclusion of many severely obese children by 
the ambulatory BP criteria for normotension. Previous stud-
ies have shown that only a small minority of adolescents with 
severe obesity is normotensive by ABPM,33 and that has been 
our experience during the ABPM screening process as well 
(data not shown).
Based on previous studies in young adults and children, 
the negative effects of HTN on neurocognitive test perfor-
mance are expected to be relatively subtle.6,9 Therefore, it is 
important to understand the impact of potentially strong 
confounders that have the potential to overshadow the effects 
of HTN on cognition, despite the plan to adjust for confound-
ing variables in the statistical models. Sleep-related breathing 
disorders represent such a potential confounder since they 
are associated with both HTN and obesity and are known 
to negatively impact cognitive function. The results of the 
current analysis show that high SDB scores were not signifi-
cantly associated with worse performance on the laboratory-
based cognitive measures employed in our ongoing study 
of neurocognition in primary HTN. This finding is reassur-
ing in that it implies that emerging differences in laboratory 
neurocognitive test performance between hypertensive and 
normotensive subjects is not confounded by the higher pro-
portion of HTN subjects with SDB.34 By contrast, high SDB 
scores were associated with worse cognition as measured by 
parent and self-ratings of executive function. The finding that 
the group of subjects who had an elevated score of ≥0.33 on 
the SRBD-PSQ were predominantly the ones who had worse 
scores on the rating scales of executive function suggests that 
OSA likely accounted for much of this effect. In addition, 
elevated SDB scores were associated with parent and self-rat-
ings of anxiety, depression, and even externalizing behaviors. 
Interestingly, an association between SDB and mood distur-
bances in children has been previously described.13
The reason for the difference in the impact of SDB on results 
for performance-based laboratory measures and that for the 
rating scales cannot be determined from the current analysis; 
however, some explanations can be reasonably postulated. 
Performance-based laboratory computer or paper-and-pencil 
Table 4. Comparison of neurocognitive test scores of subjects with elevated SRBD score to that of subjects with non-elevated SRBD scores
Neurocognitive measure by cognitive domain
SRBD score  
elevated (N = 12)






  RAVLT Long Delayed Recall 9.7 ± 2.6 10.2 ± 2.9 0.18 0.55
  CogState GMLT Delayed Recall 6.9 ± 2.7 7.1 ± 5.2 0.05 0.91
 Attention
  CPT-II Omission errors 48.9 ± 5.4 48.9 ± 7.3 0 0.99
  Spatial Span Forward 9.25 ± 1.9 9.35 ± 3 0.04 0.91
  Digit Span Forward 8.5 ± 2.3 8.6 ± 2.8 0.04 0.87
 Executive function
  CPT-II Commission errors 53.7 ± 8 51.4 ± 9.8 0.26 0.46
  Spatial Span Backward 10.2 ± 2.5 10.3 ± 2.3 0.04 0.86
  Digit Span Backwards 8.7 ± 2.7 9.8 ± 2.6 0.41 0.19
  DKEFS Tower total achievement 9.1 ± 2.2 9.4 ± 2.5 0.13 0.67
  CogState GMLT Total Error 57.7 ± 18 54.5 ± 16.8 0.18 0.56
  CogState Set Shifting Error 45.8 ± 20.2 36.3 ± 15.1 0.54 0.07
 Fine motor
  Grooved Pegboard, dominant 82.6 ± 15.6 79.1 ± 14.1 0.24 0.45
Questionnaires
 Parent BRIEF GEC 56.8 ± 9.5 48.6 ± 8 0.94 0.03
 Self BRIEF GEC 58.1 ± 9 45.5 ± 9.4 1.37 <0.01
 MASC total 49.8 ± 10 44.9 ± 8 0.54 0.07
 CDI total 52 ± 9.5 42.0 ± 6.9 1.22 <0.01
 CBCL internalizing 55 ± 11.5 49.0 ± 8.5 0.6 0.04
 CBCL externalizing 53.8 ± 10 46.0 ± 8.5 0.84 <0.01
Abbreviations: BRIEF, Behavior Rating Inventory of Executive Function; CBCL, Child Behavior Checklist; CDI, Child Depression Inventory; 
CPT-II, Conners’ Continuous Performance Test-II; DKEFS, Delis-Kaplan Executive Function System; GEC, Global Executive Composite; GMLT, 
Groton Maze Learning Test; MASC, Multidimensional Anxiety Scale for Children; RAVLT, Rey Auditory Verbal Learning Test.
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tests are administered in a structured, quiet, one-on-one 
testing environment, a setting where the cognitive effects of 
disordered sleep may not manifest and where cognitive per-
formance is optimized. By contrast, when completing the 
BRIEF,22 parents and subjects are asked to rate behaviors that 
reflect executive functioning in real-world settings over the 
preceding 6 months. The more chaotic nature of real-world set-
tings compared with the laboratory testing environment may 
allow the manifestation of the cognitive effects of disordered 
sleep, especially over the longer time period of the assessment 
period. Rater bias may also be playing a role in the correlation 
between SRBD-PSQ scores and the parent and child ratings 
scales. That is, a rater who perceives poor functioning in the 
subject in 1 area may be prone to rate the subject as having 
worse functioning across cognitive and behavioral domains.35
The current analysis has several limitations. The diagnosis of 
SDB is assessed by parent questionnaire and not by the more 
definitive method of nocturnal polysomnography. There were 
no tests conducted to distinguish between OSA and central 
sleep apnea. In addition, the cross-sectional study design does 
not allow inference of causality between the presence of SDB 
and cognitive problems. In addition, the increased prevalence 
of elevated SDB in the HTN group in our cohort cannot be gen-
eralized to the whole population of children with primary HTN. 
Our HTN group had ABPM confirmed HTN and therefore 
may have more severely elevated BP than children diagnosed 
by office readings alone. Furthermore, the sample size was too 
small to allow comparison of cognition of the HTN and con-
trol groups, at this point in enrollment. Once full enrollment 
is achieved we will be able to evaluate the difference between 
groups in cognition with statistical adjustment for SBD.
These findings suggest that SDB is a significant problem 
in children with obesity-associated primary HTN, in that a 
larger proportion of children with HTN had scores sugges-
tive of SDB. Children with primary HTN and SDB may be 
especially vulnerable to executive dysfunction in everyday 
settings. These findings underscore the importance of using 
a multi-method approach in the assessment of cognition and 
of adjusting for the potential confounding effects of SDB in 
studies investigating cognition as a possible manifestation of 
HTN target organ damage to the brain in children.
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